TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03028428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placenta Derived Mesenchymal Stem Cell
Description: 1ml 1\*10\^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate administered into the knee joint once
Study: NCT04127227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab,pegaspargase,gemcitabine,oxaliplatin
Description: All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy
Study: NCT03981172

Intervention type: BEHAVIORAL
Intervention: Daily snack food intake
Description: participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.

Intervention type: BEHAVIORAL
Intervention: Daily snack food intake
Description: participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.

Intervention type: BEHAVIORAL
Intervention: Daily snack food intake
Description: participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.

Intervention type: BEHAVIORAL
Intervention: Daily snack food intake
Description: participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
Study: NCT03160378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational skills training
Description: 10 sessions of parent and child training in a group format.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient clinic
Study: NCT02000492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Football

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit training
Study: NCT01813617

Intervention type: DRUG
Intervention: Immunosuppressive Agents
Description: Patients in the cohort received medical treatment according to standard care.
Study: NCT03218020

Intervention type: OTHER
Intervention: No intervention assigned, this is an observational study.
Description: No intervention assigned, this is an observational study.

Intervention type: OTHER
Intervention: No intervention assigned, this is an observational study.
Description: No intervention assigned, this is an observational study.
Study: NCT01965860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional curriculum (E-learning + simulation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional E-learning
Study: NCT04525534

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: There is no other intervention, only clinical treatment
Study: NCT02657486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Study: NCT02502032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different groups received different pretreatments of cisatracurium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different groups received different pretreatments of cisatracurium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Different groups received different pretreatments of cisatracurium.
Study: NCT00204490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones
Description: soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate
Description: carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
Study: NCT01880866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (-)-Epicatechin
Description: A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
Study: NCT03252405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mask ventilation
Description: before intravenous induction, mask application is made. then intravenous cannulation and induction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravenous cannulation
Description: induction is applied by using intravenous cannulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous cannulation
Description: induction is applied by using intravenous cannulation
Study: NCT05117216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Vigilant Care (Parental training)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Vigilant Care (Parental training)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technological Parental Monitoring

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technological Parental Monitoring
Study: NCT04800081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
Study: NCT03334435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT02777554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast XL
Description: Apremilast extended release formulation tablet
Study: NCT03334435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT03334435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT03863613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
Study: NCT03566628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed Isotonic Saline
Description: Isotonic saline warmed to 39ºC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room-Temperature Isotonic Saline
Description: Isotonic saline at room temperature
Study: NCT01857063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
Study: NCT02131480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1,1 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1,1 mg/m²
Study: NCT02132585

Intervention type: PROCEDURE
Intervention: Speckle tracking echocardiography

Intervention type: PROCEDURE
Intervention: Speckle tracking echocardiography
Study: NCT01528241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP688
Description: Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
Study: NCT04705285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium Yag Laser
Description: Subjets in the laser arm will undergo 2 sessions of vaginal erbium-yag laser, separated by a month

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Training
Description: Patients allocated to pelvic floor training, are goin to undergo 10 sessions of pelvic floor exercises coached by an expert physiotherapist
Study: NCT01871363

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: * radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~* capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~* bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~* Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation.
Study: NCT03151759

Intervention type: RADIATION
Intervention: Neoadjuvant radiotherapy
Description: Neoadjuvant radiotherapy prior to rectal cancer surgery

Intervention type: RADIATION
Intervention: Neoadjuvant radiotherapy
Description: Neoadjuvant radiotherapy prior to rectal cancer surgery
Study: NCT00938275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5g SRT2104
Description: SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment.
Study: NCT02472600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
Study: NCT04259398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane is administered for induction and maintenance of anesthesia
Study: NCT02516462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVM media
Description: Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone (FSH)
Description: Low dose FSH is administered to stimulate follicle growth.
Study: NCT04472910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Folforinox (mFFX)
Description: Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
Study: NCT00540982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 0.5 mg/kg will be administered by IV push to determine clearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 0.5 mg/kg will be administered by IV push to determine clearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 0.5 mg/kg will be administered by IV push to determine clearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 0.5 mg/kg will be administered by IV push to determine clearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1 mg/kg will be administered to determine metabolic capacity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1 mg/kg will be administered to determine metabolic capacity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1 mg/kg will be administered to determine metabolic capacity
Study: NCT01916447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study: NCT03334435

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02280200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFO to improve outcomes
Description: Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
Study: NCT03367676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 100mg/m2，d1，iv，q3w\*4
Study: NCT03146819

Intervention type: DEVICE
Intervention: iTotal PS Knee Replacement System
Description: Total Knee Replacement systems (Patient Specific)

Intervention type: DEVICE
Intervention: Off-the-Shelf Knee Replacement System
Description: Total Knee Replacement systems (Off-the-shelf)
Study: NCT02983357

Intervention type: RADIATION
Intervention: CT, X-Ray
Description: 2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.

Intervention type: OTHER
Intervention: Physical assessment
Description: Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.

Intervention type: OTHER
Intervention: Questionnaire
Description: Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
Study: NCT04020822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Sensor (3)
Description: Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
Study: NCT03542175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
Study: NCT04131452

Intervention type: OTHER
Intervention: Filling out the forms including IDAS-II, BAI, SF-36 and FSFI
Description: Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).

Intervention type: OTHER
Intervention: Filling out the forms including IDAS-II, BAI, SF-36 and FSFI
Description: Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
Study: NCT00270205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 standard vaccination
Description: 0.1 mg DNA/participant, 0.8 ml total administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 high-dose vaccination
Description: 0.4 mg DNA/participant, 3.2 ml total administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 high-dose vaccination
Description: 0.4 mg DNA/participant, 3.2 ml total administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 placebo vaccination
Description: Placebo vaccination administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 placebo vaccination
Description: Placebo vaccination administered subcutaneously
Study: NCT02346240

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/ mL~* Route of Administration: Subcutaneous use
Study: NCT00270205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC002 placebo vaccination
Description: Placebo vaccination administered subcutaneously
Study: NCT04543747

Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The Medtronic HVAD® System is comprised of three major components: the HVAD Pump with inflow and outflow conduits, a Controller and power sources. In addition to these components, the system includes a Monitor, Battery Charger, AC and DC power adapters, and a Carrying Case. The HVAD® System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a bridge to cardiac transplantation (BTT), myocardial recovery, or as destination therapy (DT) in patients for whom subsequent transplantation is not planned.
Study: NCT03903575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En masse anterior teeth retraction
Description: After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Step Retraction
Description: After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
Study: NCT02764606

Intervention type: BIOLOGICAL
Intervention: Serum and plasma samples
Description: Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
Study: NCT04001478

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
Study: NCT02346240

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: * Active Substance: Etanercept~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 50 mg / mL~* Route of Administration: Subcutaneous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use
Study: NCT04001478

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.